AOV.TO Amotiv Limited
- Market cap
- CAD 577M
- P/E
- -
- P/B
- 0.77x
- ROE
- -0.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is AOV.TO undervalued?
Graham numberThe Graham number of Amotiv Limited cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Amotiv Limited fundamental analysis
No fundamental analysis for Amotiv Limited yet.
Amotiv Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Amotiv Limited
Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic ca…
Full company profileAmotiv Limited financial statements
Amotiv Limited annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 5.94M | 8.63M | 12.5M | 47.5M | 200M | 243M | 294M | 328M | 371M | 450M |
| Gross Profit | 4.39M | 7.05M | 10.2M | 26.9M | 81.7M | 115M | 138M | 156M | 178M | 208M |
| Operating Income | -7.84M | -8.91M | -5.78M | 14.0M | -3.44M | -5.32M | -2.40M | 413K | 7.40M | -2.35M |
| EBITDA | 48.3M | 49.1M | 52.3M | 18.3M | 28.6M | 42.6M | 60.2M | - | - | - |
| Net Income | 18.6M | 17.2M | 24.1M | 14.5M | 31.8M | 15.7M | -29.9M | -16.8M | 4.33M | -5.37M |
| EPS | 0.15 | 0.12 | 0.17 | 0.10 | 0.24 | 0.13 | -0.26 | -0.17 | 0.04 | -0.05 |
| Balance Sheet | ||||||||||
| Total Assets | 991M | 1.01B | 1.05B | 1.31B | 1.04B | 992M | 1.05B | 945M | 964M | 1.05B |
| Total Liabilities | 11.1M | 14.8M | 21.8M | 390M | 153M | 150M | 229M | 199M | 169M | 279M |
| Shareholders' Equity | 980M | 991M | 1.03B | 811M | 886M | 842M | 826M | 747M | 795M | 767M |
| Cash & Short-term Investments | 788M | 788M | 704M | 431M | 411M | 163M | 191M | 158M | 163M | 114M |
| Total Debt | - | - | - | 62.2M | 56.2M | 41.0M | 77.7M | - | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | 14.7M | 23.5M | -5.74M | 4.60M | -12.2M | 44.6M | 40.5M | 35.9M | 36.3M | 69.0M |
| Capital Expenditure | 9.86M | 126K | 3.87M | 2.95M | 20.7M | 224M | 25.8M | 9.96M | 31.5M | 33.7M |
| Free Cash Flow | 4.88M | 23.3M | -9.61M | 1.65M | -32.9M | -180M | 14.7M | 26.0M | - | - |
| Ratios | ||||||||||
| ROE | 1.9% | 1.7% | 2.3% | 1.8% | 3.6% | 1.9% | -3.6% | -2.3% | 0.5% | -0.7% |
| ROA | 1.9% | 1.7% | 2.3% | 1.1% | 3.1% | 1.6% | -2.8% | -1.8% | 0.4% | -0.5% |
| Net Profit Margin | 312.5% | 199.7% | 192.6% | 30.6% | 15.9% | 6.4% | -10.2% | -5.1% | 1.2% | -1.2% |
| Debt to Equity | - | - | - | 0.08x | 0.06x | 0.05x | 0.09x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Amotiv Limited dividends
Amotiv Limited has not paid dividends in the last 10 fiscal years.
Who owns Amotiv Limited
- Insiders 45.48%
- Institutions 13.02%
- Public & others 41.51%
- Shares outstanding 101M
- Free float 53.1M
Amotiv Limited company profile
- Company name
- Amotiv Limited
- Ticker
- AOV.TO
- ISIN
- CA4990531069
- Exchange
- Toronto Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 725
- Fiscal year end
- December
- Address
- 3400 de Maisonneuve Boulevard West, Montreal, QC, Canada, H3Z 3B8
- Phone
- 514-484-4483
- Website
- gud-knight.com
About Amotiv Limited
Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma. The company provides Ladecvina for multiple myeloma and myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Palbocil for breast cancer; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Dolufevir for HIV infection; Exelon for dementia; and Ibsrela for irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for vasomotor symptoms; Fibridoner for idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.
Amotiv Limited management
10- Mr. Jonathan Ross Goodman B.A., L.L.B., M.B.A.Executive Chairman · born 1969
- Ms. Samira Sakhia BCom, CA, CPA, MBAPresident, CEO & Director · born 1968
- Mr. Arvind UtchanahChief Financial Officer
- Ms. Amal Khouri B.Sc., M.B.A.Chief Business Officer
- Mr. Jeff MartensGlobal Vice President of Commercial
- Mr. Stephani SaverioVice President of Business Development
- Mr. Leopoldo BosanoVice-President of Manufacturing & Operations
- Ms. Monica PercarioGlobal Vice President of Scientific Affairs
- Mr. Henrique DiasGlobal Director of Marketing
- Ms. Susan Caroline EmblemGlobal Vice President of Human Resources